Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”

This letter to the editor remarks on a recently published article about dermatologic events induced by enfortumab vedotin, comparing results from other similar studies.

Detalles Bibliográficos
Autores principales: Ingen-Housz-Oro, Saskia, Thibault, Constance, Sohier, Pierre, Dupin, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526490/
https://www.ncbi.nlm.nih.gov/pubmed/36036595
http://dx.doi.org/10.1093/oncolo/oyac170
_version_ 1784800886858448896
author Ingen-Housz-Oro, Saskia
Thibault, Constance
Sohier, Pierre
Dupin, Nicolas
author_facet Ingen-Housz-Oro, Saskia
Thibault, Constance
Sohier, Pierre
Dupin, Nicolas
author_sort Ingen-Housz-Oro, Saskia
collection PubMed
description This letter to the editor remarks on a recently published article about dermatologic events induced by enfortumab vedotin, comparing results from other similar studies.
format Online
Article
Text
id pubmed-9526490
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95264902022-10-03 Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin” Ingen-Housz-Oro, Saskia Thibault, Constance Sohier, Pierre Dupin, Nicolas Oncologist Letter to the Editor This letter to the editor remarks on a recently published article about dermatologic events induced by enfortumab vedotin, comparing results from other similar studies. Oxford University Press 2022-08-29 /pmc/articles/PMC9526490/ /pubmed/36036595 http://dx.doi.org/10.1093/oncolo/oyac170 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Letter to the Editor
Ingen-Housz-Oro, Saskia
Thibault, Constance
Sohier, Pierre
Dupin, Nicolas
Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
title Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
title_full Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
title_fullStr Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
title_full_unstemmed Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
title_short Regarding “Management of Dermatologic Events Associated with the Nectin-4–directed Antibody-Drug Conjugate Enfortumab Vedotin”
title_sort regarding “management of dermatologic events associated with the nectin-4–directed antibody-drug conjugate enfortumab vedotin”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526490/
https://www.ncbi.nlm.nih.gov/pubmed/36036595
http://dx.doi.org/10.1093/oncolo/oyac170
work_keys_str_mv AT ingenhouszorosaskia regardingmanagementofdermatologiceventsassociatedwiththenectin4directedantibodydrugconjugateenfortumabvedotin
AT thibaultconstance regardingmanagementofdermatologiceventsassociatedwiththenectin4directedantibodydrugconjugateenfortumabvedotin
AT sohierpierre regardingmanagementofdermatologiceventsassociatedwiththenectin4directedantibodydrugconjugateenfortumabvedotin
AT dupinnicolas regardingmanagementofdermatologiceventsassociatedwiththenectin4directedantibodydrugconjugateenfortumabvedotin

Ejemplares similares